UNICEL® DXL 600 ACCESS® IMMUNOASSAY SYSTEM
Report
- Report Number
- 2122870-2011-02775
- Event Type
- Malfunction
- Date Received
- August 6, 2011
- Date of Event
- July 7, 2011
- Report Date
- July 7, 2011
- Manufacturer
- BECKMAN COULTER INC.
- Product Code
- JJE
- PMA / PMN Number
- K023764
- Removal / Correction Number
- NA
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- CA, US
- Reporter Occupation
- OTHER
Narratives
SAMPLE WAS LITHIUM HEPARIN PLASMA THAT WAS ORIGINALLY CENTRIFUGED FOR 7 MINUTES AT 3850RPM. PER CUSTOMER, THE SAMPLE LOOKED CLEAR AND THERE WERE NO NOTED ISSUES WITH THE SAMPLE QUALITY. QC IS PERFORMED ONCE DAILY AND WAS WITHIN THE CUSTOMER'S ESTABLISHED RANGES DURING THIS EVENT. THE CUSTOMER PERFORMED A SYSTEM CHECK AND A 10 POINT PRECISION RUN AFTER THE ERRONEOUS RESULTS ABOVE AND BOTH MET SPECIFICATIONS. THE CUSTOMER DECLINED SERVICE AS ONLY ONE PATIENT SAMPLE WAS IN QUESTION.
A CUSTOMER CONTACTED BECKMAN COULTER INC. (BEC) REGARDING CREATINE KINASE-MB (CKMB) RESULTS GENERATED BY THE UNICEL DXL 600 ACCESS IMMUNOASSAY SYSTEM FOR ONE PATIENT'S SAMPLE. THE PATIENT'S INITIAL CKMB RESULT WAS 67.1NG/ML (TOTAL CK RESULT WAS 68NG/ML AND THE PATIENT'S PREVIOUS TOTAL CK RESULT WAS 63NG/ML.) THE CUSTOMER QUESTIONED THE RESULT AND DID NOT REPORT IT OUTSIDE OF THE LABORATORY. THE SAMPLE WAS POURED OFF AND REPEAT TESTING WAS PERFORMED. THE REPEAT CKMB RESULT WAS 68.8NG/ML AND TOTAL CK RESULT WAS 55NG/ML. THE SAMPLE WAS THEN CENTRIFUGED FOR 3 MINUTES AND THE REPEAT CKMB RESULT WAS 4.7NG/ML ON THIS INSTRUMENT AND 3.7NG/ML ON AN ALTERNATE INSTRUMENT. NO REPORTS OF PATIENT INJURY REQUIRING MEDICAL INTERVENTION OR CHANGE TO PATIENT TREATMENT HAVE BEEN ATTRIBUTED OR CONNECTED TO THIS EVENT.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | UNICEL® DXL 600 ACCESS® IMMUNOASSAY SYSTEM | DISCRETE PHOTOMETRIC CHEMISTRY ANALYZER | JJE | BECKMAN COULTER INC. | DXI 600 | NA |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |